|
TACT411
TACT411 is a monoamine transporter modulator and serotonin 5-HT1B receptor modulator which is under development for the treatment of alcohol use disorder, anorexia, and binge-eating disorder. It is being developed by Tactogen. As of the first quarter of 2025, the drug is in the preclinical research stage of development. See also * TACT833 * TACT908 * 1Z2MAP1O * List of investigational hallucinogens and entactogens This is a list of investigational hallucinogens and entactogens, or hallucinogens and entactogens that are currently under formal development for clinical use but are not yet approved. ''Chemical/generic names are listed first, with developmenta ... References 5-HT1B agonists Drugs with undisclosed chemical structures Entactogens Experimental entactogens Monoamine releasing agents {{Psychoactive-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
TACT833
TACT833 is a monoamine transporter transporter modulator, modulator and serotonin 5-HT1B receptor, 5-HT1B receptor receptor modulator, modulator which is under development for the treatment of alcohol use disorder, anorexia, and binge-eating disorder. It is being developed by Tactogen. As of the first quarter of 2025, the drug is in the preclinical research stage of development. See also * TACT411 * TACT908 * 1Z2MAP1O * List of investigational hallucinogens and entactogens References 5-HT1B agonists Drugs with undisclosed chemical structures Entactogens Experimental entactogens Monoamine releasing agents {{Psychoactive-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Experimental Entactogens
This is a list of investigational hallucinogens and entactogens, or hallucinogens and entactogens that are currently under formal development for clinical use but are not yet approved. ''Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.'' The list also includes non-hallucinogenic drugs related to hallucinogens, such as non-hallucinogenic serotonin 5-HT2A receptor agonists and non-hallucinogenic ketamine analogues. Cannabinoids, or cannabinoid receptor modulators, are not included in this list. Many of the indications are not for continuous medication therapy but rather are for medication-assisted psychotherapy or short-term use only. The section that the drug is in corresponds to its highest developmental phase, not its phase for all listed indications. This list was last comprehensively updated in October 2024. It is likely to become outdated with time. Under development Preregistration * Midomafetamine (MDMA ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
1Z2MAP1O
1Z2MAP1O, also known as 1-(indolizin-3-yl)-2-(methylamino)propan-1-one, is a monoamine releasing agent and serotonin receptor receptor modulator, modulator of the indolizine class. It is an structural analog, analogue of BK-NM-AMT (β-keto-''N''-methyl-α-methyltryptamine) in which the indole ring (chemistry), ring has been replaced with an indolizine ring. 1Z2MAP1O has been found to be a serotonin releasing agent, serotonin and dopamine releasing agent as well as a weak serotonin 5-HT1B receptor, 5-HT1B receptor agonist and serotonin 5-HT2B receptor, 5-HT2B receptor receptor antagonist, antagonist. Conversely, its activity as a norepinephrine releasing agent was not reported, and it was inactive at the remaining sites of the 47screened biological target, targets. The drug's values for induction of monoamine release were 109nM for serotonin and 227nM for dopamine in Chinese hamster ovary cell, Chinese hamster ovary (CHO) cell (biology), cells expressing the human monoamine transp ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
TACT908
TACT908, also known as -(indolizin-1-yl)ethylimethylamine (2ZEDMA), is a serotonin receptor agonist which is under development for the treatment of cluster headaches. It is an positional isomer of the famous tryptamine serotonergic psychedelic ''N'',''N''-dimethyltryptamine (DMT) in which the indole ring has been replaced with an indolizine ring. The drug acts as a serotonin 5-HT1B and 5-HT2A receptor agonist. Its at the serotonin 5-HT2A receptor is 52nM ( ≈ 30% of that of serotonin) and its at the serotonin 5-HT1B receptor is 143nM. TACT908 is said to be a non-hallucinogenic serotonin 5-HT2A receptor agonist. It showed little or no activity at 45other screened targets, including the serotonin 5-HT1A, 5-HT2B, and 5-HT3 receptors as well as the monoamine transporters (MATs). Other serotonin receptors besides the preceding, such as the serotonin 5-HT2C receptor, were not assessed. The drug was a weak monoamine oxidase inhibitor (MAOI), specifically of monoamine oxidase ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Tactogen
Tactogen is a public benefit corporation and start-up pharmaceutical company based in Palo Alto, California that is developing novel MDMA-like entactogens and psychedelics as medicines. Its stated goal is to develop new MDMA-like drugs with improved effectiveness, tolerability, and safety, as well as gentleness and accessibility, for treatment of psychiatric disorders and other conditions. Tactogen was co-founded by neuroscientist Matthew J. Baggott and Luke Pustejovsky in 2020. Baggott is the chief executive officer (CEO) while Pustejovsky is the chief operating officer (COO). Drug candidates Tactogen has patented various novel entactogen-like compounds from different chemical families. These include benzofurans like 5-MAPB, 5-MBPB, and BK-5-MAPB, benzothiophenes like 5-MAPBT, α-alkyltryptamines like BK-NM-AMT and BK-5F-NM-AMT, indolizines like 2ZEDMA, 1ZP2MA, and Z2MAP1O, 2-aminoindanes like "BFAI", and non-racemic mixtures of enantiomers. It also has several dru ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Serotonin
Serotonin (), also known as 5-hydroxytryptamine (5-HT), is a monoamine neurotransmitter with a wide range of functions in both the central nervous system (CNS) and also peripheral tissues. It is involved in mood, cognition, reward, learning, memory, and physiological processes such as vomiting and vasoconstriction. In the CNS, serotonin regulates mood, appetite, and sleep. Most of the body's serotonin—about 90%—is synthesized in the gastrointestinal tract by enterochromaffin cells, where it regulates intestinal movements. It is also produced in smaller amounts in the brainstem's raphe nuclei, the skin's Merkel cells, pulmonary neuroendocrine cells, and taste receptor cells of the tongue. Once secreted, serotonin is taken up by platelets in the blood, which release it during clotting to promote vasoconstriction and platelet aggregation. Around 8% of the body's serotonin is stored in platelets, and 1–2% is found in the CNS. Serotonin acts as both a vasoconstrictor and vas ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Alcohol Use Disorder
Alcoholism is the continued drinking of alcohol despite it causing problems. Some definitions require evidence of dependence and withdrawal. Problematic use of alcohol has been mentioned in the earliest historical records. The World Health Organization (WHO) estimated there were 283 million people with alcohol use disorders worldwide . The term ''alcoholism'' was first coined in 1852, but ''alcoholism'' and ''alcoholic'' are considered stigmatizing and likely to discourage seeking treatment, so diagnostic terms such as ''alcohol use disorder'' and ''alcohol dependence'' are often used instead in a clinical context. Alcohol is addictive, and heavy long-term alcohol use results in many negative health and social consequences. It can damage all the organ systems, but especially affects the brain, heart, liver, pancreas, and immune system. Heavy alcohol usage can result in trouble sleeping, and severe cognitive issues like dementia, brain damage, or Wernicke–Korsakoff ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Anorexia
Anorexia nervosa (AN), often referred to simply as anorexia, is an eating disorder characterized by Calorie restriction, food restriction, body image disturbance, fear of gaining weight, and an overpowering desire to be thin. Individuals with anorexia nervosa have a fear of being overweight or being seen as such, despite the fact that they are typically underweight. The DSM-5 describes this perceptual symptom as "disturbance in the way in which one's body weight or shape is experienced". In research and clinical settings, this symptom is called "body image disturbance" or Body dysmorphic disorder, body dysmorphia. Individuals with anorexia nervosa also often deny that they have a problem with low weight due to their altered perception of appearance. They may weigh themselves frequently, eat small amounts, and only eat certain foods. Some patients with anorexia nervosa Binge eating, binge eat and Purging disorder, purge to influence their weight or shape. Purging can manifest a ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Binge-eating Disorder
Binge eating disorder (BED) is an eating disorder characterized by frequent and recurrent binge eating episodes with associated negative psychological and social problems, but without the compensatory behaviors common to bulimia nervosa, OSFED, or the binge-purge subtype of anorexia nervosa. BED is a recently described condition, which was introduced to distinguish binge eating similar to that seen in bulimia nervosa but without characteristic purging. Individuals who are diagnosed with bulimia nervosa or binge eating disorder exhibit similar patterns of compulsive overeating, neurobiological features such as dysfunctional cognitive control and food addiction, and biological and environmental risk factors. Some professionals consider BED to be a milder form of bulimia, with the two conditions on the same spectrum. Binge eating is one of the most prevalent eating disorders among adults, though it receives less media coverage and research about the disorder compared to anorexia n ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Transporter Modulator
A reuptake modulator, or transporter modulator, is a type of drug which modulates the reuptake of one or more neurotransmitters via their respective neurotransmitter transporters. Examples of reuptake modulators include reuptake inhibitor Reuptake inhibitors (RIs) are a type of reuptake modulators. It is a drug that inhibits the plasmalemmal transporter-mediated reuptake of a neurotransmitter from the synapse into the pre-synaptic neuron. This leads to an increase in extracel ...s (transporter blockers) and reuptake enhancers. See also * Releasing agent * Release modulator * Transporter substrate * Channel modulator * Receptor modulator Drugs by mechanism of action Psychopharmacology {{pharmacology-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Preclinical Research
In drug development, preclinical development (also termed preclinical studies or nonclinical studies) is a stage of research that begins before clinical trials (testing in humans) and during which important feasibility, iterative testing and drug safety data are collected, typically in laboratory animals. The main goals of preclinical studies are to determine a starting, safe dose for first-in-human study and assess potential toxicity of the product, which typically include new medical devices, prescription drugs, and diagnostics. Companies use stylized statistics to illustrate the risks in preclinical research, such as that on average, only one in every 5,000 compounds that enters drug discovery to the stage of preclinical development becomes an approved drug. Types Each class of product may undergo different types of preclinical research. For instance, drugs may undergo pharmacodynamics (what the drug does to the body) (PD), pharmacokinetics (what the body does to t ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
